Pfizer Inc seeks permission for emergency use of vaccine

The Phase 3 study of our COVID19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of COVID19, with the vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose: Pfizer Inc.

The company now has 170 infections on which its data are based. Only eight infections were recorded among volunteers who got the vaccine, while only one got severe disease.